Last reviewed · How we verify
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (STORE)
The purpose of this study is to describe the effectiveness of darunavir/cobicistat (DRV/c)-based regimens, measured as maintenance of virological suppression 48 weeks after baseline, defined as the day when the treatment with DRV/c-based regimen is started, through collection of daily practice data in the Italian setting.
Details
| Lead sponsor | Janssen-Cilag S.p.A. |
|---|---|
| Status | COMPLETED |
| Enrolment | 337 |
| Start date | Fri Jul 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Feb 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Human Immunodeficiency Virus